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Purpose of the study
Preventing immunological deterioration is essential in
highly-experienced HIV-1-infected patients who have no
options for fully suppressive therapies. We explored a
holding regimen aimed to preserve the immunologic sta-
tus of patients with multidrug resistant virus while await-
ing new active drugs.
Methods
Exploratory, randomized study in heavily pretreated
patients on failing therapies. The objective was to deter-
mine if a holding regimen integrated by co-formulated
zidovudine/lamivudine/abacavir and tenofovir was able
to maintain immunological status. Virologic outcomes,
genotype evolution and clinical safety were also evalu-
ated. Control arm received a genotype-guided salvage reg-
imen.
Summary of results
Twenty-three patients (pts) were recruited; 13 were
assigned to the holding-arm and 10 to the control-arm.
76% and 80%, respectively, had ≥3 TAMs at baseline (BL).
Genotype sensitive score was 0.5 (0.5; 0.75) and 0.5 (0.5;
1), respectively. Median (IQR) BL CD4 count was 366
(293; 448) in holding- and 420 (189; 456) cells/μL in
control-arm (p = 0.9), and median BL viral load (VL) was
3.5 (3; 4) and 4.12 log10 (3.3; 4.5), respectively. After 48
weeks, 62% in the holding- and 100% of the control-arm
maintained their CD4 count (p = 0.09). VL decreased a
median of 0.6 (0.2; 1.9) and 2 log10 (0.5; 2.7) in the
holding- and control-arm (p = 0.1). 27% of the pts in the
holding- and 50% in control-arm achieved undetectable
VL. Number of TAMs and mutations in the protease gene
were maintained in both groups. No clinical progression
was observed. Adverse events were detected in 16% in
holding- and 90% in control-arm, respectively (p =
0.001). When a fully suppressive therapy could be initi-
ated, 69% of the pts from holding-arm (nine subjects)
and 60% (six pts) from the control-arm achieved VL<50
copies at 48 weeks of follow-up after the study ending.
Conclusion
Our results showed better virological and immunological
outcomes with standard salvage therapy than a holding
therapy with TZV+TDF. However, this approach provided
a stable immunologic status, better tolerability and it was
not associated with clinical progression for 48 weeks of
follow-up. This strategy did not jeopardize a posterior
complete viral suppression when a fully active regimen
could be initiated. This transient approach could be useful
in pts with multidrug resistant HIV-1, toxicities or other
condition that restrict active drugs while awaiting a fully
suppressive regimen.
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